The Exchange had sought clarification from Aarey Drugs & Pharmaceuticals Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The National Stock Exchange had sought clarification from Aarey Drugs regarding discrepancies in the financial results filed on 11 February 2026 for the quarter ended 31 December 2025. The company admitted there was a mismatch in Profit After Tax (PAT) figures between the PDF and XBRL versions of the filing. The company attributed this to an inadvertent clerical error and clarified they have now uploaded revised Integrated Financial Results with acknowledgement number 150465. This is a procedural correction rather than a fundamental restatement of financials.
The clerical error appears minor and has been corrected promptly, which limits potential damage. However, such discrepancies in financial filings may raise concerns about the company's internal controls and data management processes among investors.